The past 3 years have witnessed the addition of four new agents—ipilimumab, vemurafenib, dabrafenib (Tafinlar), and trametinib (Mekinist)—to the therapeutic repertoire for advanced melanoma, two of which are selective BRAF kinase inhibitors. This evidence concerns the gene BRAF and melanoma.